Drug Trial Radar · NCT06009094
Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jul 27, 2023
Primary completion
May 23, 2024
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.
Conditions
- Atopic Dermatitis
Interventions
VC005Drug
VC005 group with Local topical application
VC005 PlaceboDrug
VC005 Placebo group with Local topical application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax)Time frame: Day2,Day 4,Day17,Day31
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences Hospital of Skin Disease
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.